Search Within

Melanoma Disease Management Team

Formats
  1. Journal Article (1604)
  2. Meeting Abstract (791)
  3. Book Section (104)
  4. Review (72)
  5. Editorial (58)
  6. Research Letter (45)
  7. Guidelines (26)
  8. Conference Paper (22)
  9. Correspondence (21)
  10. Miscellaneous (16)
  11. Book Whole (11)
Groups
  1. Department of Medicine (1690)
  2. Survivorship Research (1193)
  3. Solid Tumor Oncology Division (1052)
  4. Department of Pathology and Laboratory Medicine (957)
  5. Surgery (947)
  6. Melanoma and Immunotherapeutics Service (793)

More Groups

People
  1. Klaus Busam (698)
  2. Daniel Coit (543)
  3. Allan Halpern (401)
  4. Michael Postow (369)
  5. Alexander Shoushtari (247)
  6. Jedd Wolchok (222)

More People

Years
  1. 2025 (89)
  2. 2024 (138)
  3. 2023 (160)
  4. 2022 (167)
  5. 2021 (149)
  6. 2020 (142)

More Years

Publications
  1. Journal of Clinical Oncology (269)
  2. Annals of Surgical Oncology (221)
  3. Journal of the American Academy of Dermatology (123)
  4. Journal of Investigative Dermatology (84)
  5. Modern Pathology (67)
  6. American Journal of Surgical Pathology (64)

More Publications

Publishers
  1. Springer (341)
  2. American Society of Clinical Oncology (284)
  3. Elsevier Inc. (231)
  4. Lippincott Williams & Wilkins (229)
  5. Wiley Blackwell (162)
  6. Elsevier Science, Inc. (160)

More Publishers

Results (2770)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Less, but better: A simplified design for T cell redirection and conditional payload delivery
    Editorial

    Kropp, K. N.; Klebanoff, C. A.
    Cancer Cell (2022)

    Fulltext@MSK | Save
  • Capturing uveal melanoma (UM) global practice patterns and clinical outcomes in the collaborative ocular melanoma natural history (OMNi) study (NCT04588662)
    Meeting Abstract

    Sacco, J. J.; Orloff, M. M.; Patel, S. P.; Conway, M.; Lim, L. A.; Fog, L. S.; Sia, D.; McKenzie, J.; McKay, D.; O'Day, R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Overall survival (OS) in metastatic uveal melanoma: A summary of recent prospective trials
    Meeting Abstract

    Piulats, J. M.; Shoushtari, A. N.; Ochsenreither, S.; Abdullah, S. E.; Holland, C.; McCully, M. L.; Baurain, J. F.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Assessing PD-L1 without a biopsy and through PD-L1 PET imaging with 18F-BMS-986229
    Meeting Abstract

    Postow, M. A.; Mauguen, A.; Frosina, D.; Jungbluth, A. A.; Busam, K. J.; Pandit Taskar, N.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM)
    Meeting Abstract

    Middleton, M. R.; Hamid, O.; Shoushtari, A. N.; Meier, F. E.; Bauer, T. M.; Salama, A. K. S.; Kirkwood, J. M.; Ascierto, P. A.; Lorigan, P.; Mauch, C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Interim analysis of a single-center, single-arm, prospective phase 2 study to evaluate the efficacy and safety of benralizumab for alpelisib rash in metastatic PIK3CA-mutant, hormone receptor-positive breast cancer
    Meeting Abstract

    Lacouture, M. E.; Pan, A.; Dranitsaris, G.; Harris, U.; Chandarlapaty, S.; Dang, C. T.; Gajria, D.; Gordon, A.; Iyengar, N. M.; Robson, M. E.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • MERLIN_001: A prospective registry study of a primary melanoma gene-signature to predict sentinel node (SN) status and determine its prognostic value for more accurate staging of patients with SN-negative melanoma
    Meeting Abstract

    Hieken, T. J.; Egger, M. E.; Angeles, C. V.; Lowe, M. C.; Burke, E. E.; Bartlett, E.; Hyngstrom, J. R.; Sondak, V. K.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Clinical characteristics and treatment outcomes in patients with histiocytic neoplasms harboring class 3 MAP2K1 mutations, including treatment with the ERK inhibitor ulixertinib
    Meeting Abstract

    Diamond, E. L.; Yabe, M.; Petrova-Drus, K.; Rosenblum, M.; Rotemberg, V.; Lacouture, M. E.; Rampal, R.; Francis, J.; Knoerzer, D.; Kreider, B.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Examination of speakership gender disparity at an international oncology conference
    Meeting Abstract

    Caro, J.; Boatwright, C.; Li, X.; Fiocco, C.; Stempel, J. M.; Stoeckle, J. H.; Smithy, J. W.; Warner, A. B.; Shum, E.; Sabari, J. K.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Prophylactic radiation therapy vs. standard-of-care for patients with high-risk, asymptomatic bone metastases: A multicenter, randomized phase II trial
    Meeting Abstract

    Gillespie, E. F.; Mathis, N. J.; Marine, C.; Zhang, Z.; Barker, C. A.; Guttmann, D. M.; Kotecha, R.; McIntosh, A. F.; Vaynrub, M.; Bartelstein, M.; more...
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save